Equity Insider Flags RVMD NDA, ONCY Data, KRAS Market Growth

Equity Insider cites forecasts of the KRAS inhibitors market reaching ~$7.85B by 2034, notes FDA acceptance of Revolution Medicines' NDA for daraxonrasib in pancreatic cancer, and reports Oncolytics' positive preclinical pelareorep/pan-RAS combo data.Material DetailsContext by AI AnalystThis is a s…